QNRX יחס מהיר Quoin Pharmaceuticals Ltd

The financial stability of Quoin Pharmaceuticals (QNRX) is under pressure due to research costs for rare dermatological pathologies, and the separate_ratio_quick indicator stands at 1.80. The business relies on the exclusivity of FDA rights, which eliminates price wars with market behemoths. This price chart complements the analysis of the company, which minimizes capital expenditures by outsourcing production and testing to third-party contractors.

This metric is sensitive to operating cash flows, excluding illiquid inventories from the calculation. It measures the company's ability to settle short-term obligations using available funds and accounts receivable. For Quoin Pharmaceuticals (QNRX), which develops unique drugs for rare skin diseases, such a metric confirms financial stability despite high R&D expenditures. By analyzing the history of quick ratio changes, an investor assesses the business's actual solvency.